Janet Huancachoque Molina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Janet Huancachoque Molina has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Pool Marcos-Carbajal
Laboratorio de Investigación en Biología Molecular Lurigancho-Chosica Universidad Peruana Unión
2 shared publications - Alberto Salazar-Granara
Centro de Investigación en Medicina de Altura (CIMA), Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima 15001, Peru
1 shared publication - Alejandra Dávila-Barclay
Microbial Genomics Laboratory, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru; One Health Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru
1 shared publication - Alexander Briones
Hospital Regional de Loreto, Loreto 16004, Peru
1 shared publication - Antonio Burgos
Hospital Regional de Pucallpa, Ucayali 25001, Peru
1 shared publication - Daisy Obispo
Centro de Genética y Biología Molecular, Facultad de Medicina Humana, Universidad de San Martin de Porres, Lima 15024, Peru
1 shared publication
Latest Publications
- Open Access
- 19 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1573
Exploratory Genomic Characterisation of the Resistome, Virulome and Molecular Epidemiology of Multidrug-Resistant Klebsiella pneumoniae Clinical Isolates from Four Peruvian Regions
Multidrug-resistant (MDR) Klebsiella pneumoniae is a critical cause of nosocomial infections associated with high mortality. Of particular concern is the genomic convergence of multidrug resistance and hypervirulence (MDR-hvKP), which represents a severe public health threat. This study characterised the resistome, virulome, and population structure of seven clinical MDR K. pneumoniae isolates collected between 2024 and 2025 across four Peruvian regions (Moquegua, Ucayali, Loreto, and Lima) using whole-genome sequencing (WGS). Genomic analysis identified six distinct sequence types, with the high-risk clone ST307 being the most prevalent (2/7 isolates), consistently associated with the KL102 capsular locus. Remarkably, one isolate from Loreto (oph_54) exhibited a convergent MDR-hvKP genomic profile (ST218, KL57, virulence score 4), carrying yersiniabactin, salmochelin (iro), and aerobactin (iuc) loci alongside multiple resistance determinants. The isolates presented a robust resistome dominated by the extended-spectrum beta-lactamase gene blaCTX-M-15 (5/7) and blaOXA-1, coupled with aac(6′)-Ib-cr and fosA6 genes. Plasmid analysis revealed a predominance of IncFIB(K) replicons. Although exploratory, these findings demonstrate the regional presence of high-risk ST307 lineages and the emergence of convergent MDR-hvKP genomic profiles within the analysed Peruvian hospitals. Immediate and continuous genomic surveillance is urgently required to monitor the potential spread of these highly dangerous, MDR bacterial lineages within these healthcare environments.
- 19 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1573
Open AccessExploratory Genomic Characterisation of the Resistome, Virulome and Molecular Epidemiology of Multidrug-Resistant Klebsiella pneumoniae Clinical Isolates from Four Peruvian Regions
Multidrug-resistant (MDR) Klebsiella pneumoniae is a critical cause of nosocomial infections associated with high mortality. Of particular concern is the genomic convergence of multidrug resistance and hypervirulence (MDR-hvKP), which represents a severe public health threat. This study characterised the resistome, virulome, and population structure of seven clinical MDR K. pneumoniae isolates collected between 2024 and 2025 across four Peruvian regions (Moquegua, Ucayali, Loreto, and Lima) using whole-genome sequencing (WGS). Genomic analysis identified six distinct sequence types, with the high-risk clone ST307 being the most prevalent (2/7 isolates), consistently associated with the KL102 capsular locus. Remarkably, one isolate from Loreto (oph_54) exhibited a convergent MDR-hvKP genomic profile (ST218, KL57, virulence score 4), carrying yersiniabactin, salmochelin (iro), and aerobactin (iuc) loci alongside multiple resistance determinants. The isolates presented a robust resistome dominated by the extended-spectrum beta-lactamase gene blaCTX-M-15 (5/7) and blaOXA-1, coupled with aac(6′)-Ib-cr and fosA6 genes. Plasmid analysis revealed a predominance of IncFIB(K) replicons. Although exploratory, these findings demonstrate the regional presence of high-risk ST307 lineages and the emergence of convergent MDR-hvKP genomic profiles within the analysed Peruvian hospitals. Immediate and continuous genomic surveillance is urgently required to monitor the potential spread of these highly dangerous, MDR bacterial lineages within these healthcare environments.
- Open Access
The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America
We report the emergence of a novel lineage of SARS-CoV-2 in South America, termed C.37. It presents seven nonsynonymous mutations in the Spike gene (Δ247-253, G75V, T76I, L452Q, F490S, T859N) and a deletion in the ORF1a gene (Δ3675-3677) also found in variants of concern (VOCs) Alpha, Beta, and Gamma. Initially reported in Lima, Peru, in late December 2020, it now accounts for 97% of Peruvian public genomes in April 2021. It is expanding in Chile and Argentina, and there is evidence of onward transmission in Colombia, Ecuador, Mexico, the USA, Germany, and Israel. On June 15, 2021, the World Health Organization designated C.37 as Variant of Interest (VOI) Lambda.
Open AccessThe Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America
We report the emergence of a novel lineage of SARS-CoV-2 in South America, termed C.37. It presents seven nonsynonymous mutations in the Spike gene (Δ247-253, G75V, T76I, L452Q, F490S, T859N) and a deletion in the ORF1a gene (Δ3675-3677) also found in variants of concern (VOCs) Alpha, Beta, and Gamma. Initially reported in Lima, Peru, in late December 2020, it now accounts for 97% of Peruvian public genomes in April 2021. It is expanding in Chile and Argentina, and there is evidence of onward transmission in Colombia, Ecuador, Mexico, the USA, Germany, and Israel. On June 15, 2021, the World Health Organization designated C.37 as Variant of Interest (VOI) Lambda.